Slide 1: Transforming the Future of Chronic Kidney Disease Treatment
Transforming the Future of Chronic Kidney Disease Treatment Preserving Kidney Function in Patients at High Risk of Kidney Failure Corporate Presentation August 2026 NASDAQ PROK Copyright © 2026 ProKidney Corp. All rights reserved.
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you
Slide 3: Advanced CKD Patients Want More Time
Advanced CKD Patients Want More Time More time before dialysis More time for life’s moments More time and flexibility with the people who matter most Time for Hope 3
Slide 4: Rilparencel: Buying Meaningful Time For CKD Patients
Rilparencel: Buying Meaningful Time NOVEL autologous cell therapy made from a patient’s own kidney cells CLINICAL DATA shows kidney function stabilization in multiple Phase 2 studies WELL-TOLERATED with no preconditioning or immunosuppression required PHASE 3 STUDY is ongoing with pivotal topline re
Slide 5: Transforming CKD Care with Innovation and Execution
ProKidney Transforming Chronic Kidney Disease (CKD) Care with Innovation and Execution Rilparencel First-in-class autologous cell therapy (RMAT designation) Pivotal Phase 3 trial in Stage 3b/4 CKD ONGOING Advancing Pipeline (Type 2 Diabetes) in Stage 3/4 CKD Three Phase 2 trials in Stage 3/4 CKD C
Slide 6: 2025 Was a Pivotal Year at ProKidney
ProKidney 2025 Was a Pivotal Year at ProKidney Aligned with FDA on an accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpoint in the Phase 3 PROACT 1 study Presented positive Phase 2 REGEN-007 data as a late-breaking clinical trial at American Society of Nephrology (A
Slide 7: Well Positioned to Deliver on Milestones in 2026 and Beyond
Well Positioned to Deliver on Milestones in 2026 and Beyond Mid-2026 2026 Completed enrollment for the Phase 3 PROACT 1 accelerated approval efficacy analysis, which is 2H 2026 expected to include ~320 patients Complete enrollment for Phase 3 PROACT 1 Throughout FY 2026 confirmatory approval analysi
Slide 8: Significant Unmet Need and Limitations with Standard-of-Care
CHRONIC KIDNEY DISEASE Significant Unmet Need and Limitations with Standard-of-Care
Slide 9: Addressing Unmet Need in Advanced Kidney Disease
Addressing Unmet Need Persistent albuminuria categories Description and range in Advanced Kidney A1 A2 30–300 mg/g A3 >300 mg/g Disease <30 mg/g 3–30 mg/ >30 mg/ <3 mg/mmol mmol mmol Normal to Moderately Severely mildly increased increased increased G1 ≥90 Normal or high GFR categories (mL/min/1.73m
Slide 10: Limited Therapeutic Options Studied in Patients with Stage 4 CKD
Limited Therapeutic Options Studied in Patients with Stage 4 CKD Study Active Product Subjects with Stage 4 CKD Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy1 Canagliflozin (SGLT2 inhibitor) 0% Dapagliflozin in Patients with CKD2 Dapagliflozin (SGLT2 inhibitor) 14% Empagliflozi
Slide 11: While New Therapies Are a Step Forward, Patients Still Lose Kidney Function
While New Therapies Are a Step Forward, Patients Still Lose Kidney Function and Experience Clinically Significant Events SGLT2 inhibitors Do Not Prevent Progression of Advanced CKD Standard of Care has Limitations Patients continue to lose kidney function on SGLT2 inhibitors and Current standard of
Slide 12: Transforming the Chronic Kidney Disease Treatment Landscape
R I L PA R E N C E L R E N A L AU TO LO G O U S C E L L T H E R A PY Transforming the Chronic Kidney Disease Treatment Landscape
Slide 13: Rilparencel: A Patient's Own Cells—From Biopsy to Kidney Therapy
Rilparencel: A Patient’s Own Cells—From Biopsy to Kidney Therapy Process Overview NOT ALL CELL Kidney cells Then frozen for THERAPIES ARE x are isolated preservation and and expanded shipping to site 22 33 CREATED EQUAL Rilparencel: • Made from a patient’s own kidney cells • No genetic modification
Slide 14: Continued Expansion of In-House Manufacturing Facilities
Sam Brown spruce Continued Expansion of In-House Manufacturing Facilities up /up photo Purpose-built, scalable manufacturing infrastructure supporting Phase 3 study execution and longer-term commercialization • Purchased two adjacent buildings in Winston-Salem, NC in November 2024, totaling approxim
Slide 15: Advancing Kidney Care: Rilparencel Trials at a Glance
Advancing Kidney Care: Rilparencel Trials at a Glance PRECLINICAL IND PHASE 1 PHASE 2 PHASE 3 STATUS Pivotal Trial Program Diabetes Type II – Prevent/Delay ESKD in Stage 3b/4 CKD 006/PROACT 1 Ongoing (20-35 mL/min/1.73m2, n=~470) Long term follow-up study for patients previously treated with rilpare
Slide 16: REGEN-006 (PROACT 1) Rilparencel Registrational Program
REGEN-006 (PROACT 1) Rilparencel Registrational Program Topline results for the eGFR slope surrogate endpoint anticipated in Q2 2027 1st 2nd Rilparencel Rilparencel Rilparencel Cohort Biopsy Injection Injection n=~470 End of Study (EOS) 3 3 3 months months months Screening R Sham 1st Sham 2nd Visit
Slide 17: Increased Investment in R&D to Improve Understanding of Rilparencel MOA
Increased Investment in R&D to Improve Understanding of Rilparencel MOA In vitro Ex vivo In vivo (rodent) In vivo (human decedent) Primary kidney cells Kidney biopsy explant culture Rodent models of CKD CKD donor Control Rilparencel Kidney-on-chip Advantages • Quick: Fast design-test-learn cycles •
Slide 18: Advancing Cell Therapy For Chronic Kidney Disease
R I L PA R E N C E L C L I N I C A L R E S U LT S Advancing Cell Therapy For Chronic Kidney Disease
Slide 19: Clinical Progression: From Proof to Pivotal
Clinical Progression: From Proof to Pivotal Phase 2 RMCL-002: Full results presented at ERA Stockholm 2024 2024 SIGNAL Potential to preserve kidney function for 18 months; benefit to kidney function was most notable in subjects who had the highest risk of kidney failure SAFETY Comparable to kidn
Slide 20: REGEN-007 Trial Design
REGEN-007 Trial Design Group 1 Dosing Regimen and Use of Cryopreserved Product Mirrors Phase 3 Program Key Entry Criteria Group 1 1st & 2nd (Phase 3 Dosing Rilparencel Type 1 or type 2 diabetes and CKD Injections EOS Regimen) Biopsy Subjects 30-80 years of age n = 24* eGFR ≥20 and ≤50 mL/min/1.73m2
Slide 21: REGEN-007 Objectives and Endpoints
REGEN-007 Objectives and Endpoints Study Primary Primary Objective Efficacy Safety Evaluate the efficacy, Endpoint Endpoint safety, and durability Difference in annual Frequency of of up to two eGFR slope in the procedural and rilparencel injections pre-injection period investigational on progressio
Slide 22: REGEN-007 Baseline Characteristics
REGEN-007 Baseline Characteristics REGEN-007 (n=49) Group 1 (n=24) Group 2 (n=25) Age, years (mean +/- SD) 62 +/- 11 58 +/- 11 Female : Male, % 33% : 67% 28% : 72% Hispanic or Latino, % 0% 4% Race, % Black or African American 8% 16% White 92% 84% Other 0% 0% Type 1 Diabetes : Type 2 Diabetes, % 13%
Slide 23: Kidney Function Stabilized in Both Groups After Treatment with Rilparencel
REGEN-007 Kidney Function Stabilized in Both Groups After Treatment with Rilparencel Group 1 Group 2 (Phase 3 Dosing Regimen; n=24) (Exploratory Dosing Regimen; n=25) Annual decline in eGFR slope1 improved by 78% from -5.84 Annual decline in eGFR slope1 improved by 50% from -3.40 in the pre-injectio
Slide 24: Kidney Function Stabilizes for Months After Treatment with Rilparencel
REGEN-007 Kidney Function Stabilizes for 18 Months After Treatment with Rilparencel Group 1 Group 2 (n=24) (n=25) 15 15 Pre First-Injection Period eGFR Slope (95% CI): -3.40 (-5.03, -1.77) Pre First-Injection Period eGFR Slope (95% CI): -5.84 (-7.97, -3.70) Period After the Last-Injection eGFR Slope
Slide 25: In Group 1, Meaningful Differences in eGFR Slope Across Most Subgroups
REGEN-007 In Group 1, Meaningful Differences in eGFR Slope Were Observed Across Most Subgroups Group 1 (n=24) Slope Difference (95% CI) No. of Participants (%) Type 1 Diabetes 2.6 (-1.2, 6.4) 3 (13) Type 2 Diabetes 4.9 (2.0, 7.9) 21 (88) CKD Stage: eGFR G2 Not evaluable 0 CKD Stage: eGFR G3a Not eva
Slide 26: Group 1 SGLT2i Use Summary
REGEN-007 Group 1 | SGLT2i Use Summary • Ten patients (42%) were on SGLT2i at baseline; 3 of these 10 patients discontinued SGLT2i after receiving rilparencel • An additional 8 patients (33%) initiated SGLT2i after receiving rilparencel • In total, 18 patients (75%) received SGLT2i at some point dur
Slide 27: Baseline Characteristics: Patients Meeting Key PROACT 1 Inclusion Criteria
REGEN-007 Baseline Characteristics: Patients Meeting Key Phase 3 PROACT 1 Inclusion Criteria PROACT 1 Subgroup (n=22) Group 1 (n=15) Group 2 (n=7) Age, years (mean +/- SD) 65 +/- 9 60 +/- 7 Female : Male, % 40% : 60% 29% : 71% Hispanic or Latino, % 0% 0% Race, % Black or African American 13% 29% Whi
Slide 28: Similar Efficacy Results in Patients Meeting Key PROACT 1 Inclusion Criteria
REGEN-007 Similar Efficacy Results Were Observed in Patients Meeting Key Phase 3 PROACT 1 Inclusion Criteria GROUP 1 GROUP 2 (Phase 3 Dosing Regimen; n=15) (Exploratory Dosing Regimen; n=7) Annual decline in eGFR slope1 improved by 85% from -6.46 Annual decline in eGFR slope1 improved by 57% from -7
Slide 29: No Rilparencel-Related Serious Adverse Events Were Observed
REGEN-007 No Rilparencel-Related Serious Adverse Events Were Observed Biopsy Rilparencel Injection Rilparencel # of SAEs # of SAEs # of SAEs Adverse Event (n=51) (n=49) (n=49) Acute Kidney Injury 2 - - Death - - - Hematoma 2 1 - Hematuria 1 - - Hydronephrosis 1 - - 29
Slide 30: Clinical Confidence, Strategic Path Forward
REGEN-007 Clinical Confidence, Strategic Path Forward Key Findings Next Steps Bilateral dosing of cryopreserved → FOCUS on the continued enrollment of product (which mirrors the Phase 3 patients in our registrational Phase 3 study dosing regimen) resulted in PROACT 1 study stabilized kidney functi
Slide 31: Financial Snapshot
EXECUTING WITH STRENGTH Financial Snapshot
Slide 32: Strong Balance Sheet, Clear Path to Value Creation
Strong Balance Sheet, Clear Path to Value Creation KEY FINANCIALS KEY MILESTONES Shares Outstanding 302,322,655* 2H Complete full enrollment for 2026 the Phase 3 PROACT 1 study Cash Position $182M** Runway Phase 3 PROACT 1 topline Expected to fund operations into Q2 mid-2027 2027 data readout of sur
Slide 33: Patients Want More Time
Patients Want More Time We are building a future where advanced CKD treatment means more options and more hope 33